Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm
;
Christian
Holm Hansen
;
Henry
Bern
;
Julie
Fox
;
David
Dunn
;
Eugene
Ruzagira
;
Richard
Hayes
;
Sheena
Mc Cormack
;
Glenda
Gray
;
Nishanta
Singh
;
+98 more...
Zakir
Gaffoor
;
Neetha
Morar
;
Thandiwe
Sithole
;
Kubashni
Woeber
;
Samantha
Siva
;
Eldi-nah
Hwengwere
;
Rujeko Samanthia
Chidawanyika
;
Nteboheleng
Mahapa
;
Phindile
Khanyile
;
Janet
Seeley
;
Lucas
Maganga
;
Wiston
William
;
Emmanuel
Kapesa
;
Elizabeth
Danstan
;
Doreen
Pamba
;
Marco Missanga Amani
Kway
;
Abisai
Kisinda
;
Lilian
Njovu
;
Lwitiho
Sudi
;
Revocatus
Kunambi
;
Jane
Ambindwile
;
Said
Aboud
;
Patricia
Munseri
;
Eligius
Lyamuya
;
Frank
Msafiri
;
Agricola
Joachim
;
Edith
Tarimo
;
Diana Faini Tumaini
Nagu
;
Deus
Buma
;
Muhammad
Bakari
;
Pontiano
Kaleebu
;
Freddie Mukasa
Kibengo
;
Ayoub
Kakande
;
Jennifer
Serwanga
;
Janet
Seeley
;
Rachael
Kawuma
;
Sylvia
Kusemererwa
;
Anita
Kabarambi
;
Martin
Onyango
;
Jonathan
Kitonsa
;
Sylvia
Masawi
;
Vincent
Basajja
;
Tobias
Vudriko
;
Peter
Hughes
;
Florence
Nambaziira
;
Shamim
Nabukenya
;
Gertrude
Mutonyi
;
Rita
Nakiboneka
;
Susan
Mugaba
;
Sarah
Nakamanya
;
Denis
Kibuuka
;
Bernadette
Kalanzi
;
Ilesh
Jani
;
Edna
Viegas
;
Isabel
Remane
;
Odete
Bule
;
Edna
Nhacule
;
Patricia
Ramgi
;
Raquel
Chissumba
;
Eduardo
Namalango
;
Yolanda
Manganhe
;
Carmelia
Massingue
;
Igor
Capitine
;
Jorge
Ribeiro
;
Jonathan
Weber
;
Cherry
Kingsley
;
Thomas E
Miller
;
Sarah
Joseph
;
Claire
Wenden
;
Giuseppe
Pantaleo
;
Song
Ding
;
James S
Rooney
;
Alex
Kintu
;
Iera
Monasterio
;
Lisette
Bassi
;
Arne
Kroidl
;
Merlin
Robb
;
Charlotta
Nilsson
;
Carter
Lee
;
Vineeta
Gulati
;
Gustavo
Doncel
;
Jessica
Maitz
;
Annie
Thurman
;
Sheena
McCormack
;
Simona
Salomone
;
Angela
Crook
;
David
Dunn
;
Henry
Bern
;
Aminata
Sy
;
Liz
Brod-nicki
;
Julie
Fox
;
Kundai
Chinyenze
;
Jacqueline
Musau
;
Mabela
Matsoso
;
Mary
Amondi
;
Ansuya
Naidoo
;
Paramesh
Chetty
;
Anne
Gumbe
;
(2025)
Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm.
HIV Research & Clinical Practice, 26 (1).
2513684-.
ISSN 2578-7489
DOI: 10.1080/25787489.2025.2513684
<h4>Background</h4>Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of Emtricitabine/Tenofovir (TDF/FTC) in active-controlled pre-exposure prophylaxis (PrEP) trials has been suggested. However, it has not yet been widely applied. In this article, we evaluate adherence to TDF/FTC in the PrEPVacc trial (NCT04066881) and consider how such adherence data could be used to estimate the effectiveness of TDF/FTC and subsequently, HIV incidence in a counterfactual placebo arm in a predominantly female population.<h4>Methods</h4>From December 2020 to March 2023 participants were recruited into the trial which included a comparison of Emtricitabine/Tenofovir Alafenamide (TAF/FTC) to TDF/FTC as PrEP over 26 weeks of follow-up, in Uganda, Tanzania, and South Africa. PrEP adherence was assessed in various ways.<h4>Results</h4>Of 697 participants dispensed TDF/FTC, 87% were female, 54% were ≥ 25 years, and 59% were sex workers. In a random sample (41%) assessed at visit 6 (week 8), 76% had detectable TFV-DP levels, with 22% reaching levels consistent with ≥2 pills/week. Males, Verulam and Mbeya participants, those ≥ 25 years, not single, subsistence fisheries workers, and those who had any STI at baseline were more likely to have higher adherence. Of those assessed at visit 6, 29% were identified as white coat dosing. Estimated (crude) HIV incidence risk reduction ranged from 10% to 65%.<h4>Conclusions</h4>TDF/FTC adherence in the PrEPVacc trial was low, with considerable levels of white coat dosing. Inferring the counterfactual placebo HIV incidence using the estimated effectiveness of TDF/FTC is a promising approach, however, the approach requires further elaboration and evaluation.
-
picture_as_pdf - Kansiime-etal-2025-Evaluating-adherence-in-an-active-controlled.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 4.0